/GE%20HealthCare%20Technologies%20Inc%20info%20on%20phone-by%20T_Schneider%20via%20Shutterstock.jpg)
Chicago, Illinois GE HealthCare Technologies Inc. (GEHC) designs medical imaging and patient-monitoring products and related equipment and services. Valued at $34.4 billion by market cap, GEHC has a leading share in the imaging and ultrasound equipment market. The company is set to announce its second-quarter results before the market opens on Wednesday, Jul. 30.
Ahead of the event, analysts expect the healthcare major to deliver a profit of $0.91 per share, down 9% from $1 per share reported in the year-ago quarter. On the positive note, the company has a solid earnings surprise history. It has surpassed the Street’s bottom-line estimates in each of the past four quarters.
For the full fiscal 2025, analysts expect GEHC to deliver an EPS of $4.02, down 10.5% from $4.49 reported in the previous year. While in fiscal 2026, its earnings are expected to rebound 12.2% year-over-year to $4.51 per share.
GEHC stock has observed a 1.8% dip over the past 52 weeks, performing slightly better than the Health Care Select Sector SPDR Fund’s (XLV) 6.5% decline, but lagging behind the S&P 500 Index’s ($SPX) 12.3% returns during the same time frame.
GE Healthcare observed a solid start to the year, its stock prices gained 3.3% after the release of its Q1 results on Apr. 30. Driven by strengthening sales in the U.S., the company’s organic revenues observed a notable boost; its overall sales for the quarter grew 2.7% year-over-year to $4.8 billion. Furthermore, driven by the impact of leverage, its adjusted EPS increased 12.2% year-over-year to $1.01, surpassing the consensus estimates by 11%.
The stock holds a consensus “Strong Buy” rating overall. Of the 19 analysts covering the GEHC stock, opinions include 13 “Strong Buys,” one “Moderate Buy,” and five “Holds.” Its mean price target of $87.16 suggests a 15.4% upside potential from current price levels.
On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
